Your browser doesn't support javascript.
loading
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer, Sara C; Keller, Matthew D; Chiu, Sophia; Koppikar, Priya; Guryanova, Olga A; Rapaport, Franck; Xu, Ke; Manova, Katia; Pankov, Dmitry; O'Reilly, Richard J; Kleppe, Maria; McKenney, Anna Sophia; Shih, Alan H; Shank, Kaitlyn; Ahn, Jihae; Papalexi, Eftymia; Spitzer, Barbara; Socci, Nick; Viale, Agnes; Mandon, Emeline; Ebel, Nicolas; Andraos, Rita; Rubert, Joëlle; Dammassa, Ernesta; Romanet, Vincent; Dölemeyer, Arno; Zender, Michael; Heinlein, Melanie; Rampal, Raajit; Weinberg, Rona Singer; Hoffman, Ronald; Sellers, William R; Hofmann, Francesco; Murakami, Masato; Baffert, Fabienne; Gaul, Christoph; Radimerski, Thomas; Levine, Ross L.
Afiliação
  • Meyer SC; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Keller MD; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Chiu S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Koppikar P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Guryanova OA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Rapaport F; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Xu K; Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Manova K; Molecular Cytology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Pankov D; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • O'Reilly RJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Kleppe M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • McKenney AS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Shih AH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Shank K; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ahn J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Papalexi E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Spitzer B; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Socci N; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Viale A; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Mandon E; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Ebel N; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Andraos R; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Rubert J; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Dammassa E; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Romanet V; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Dölemeyer A; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Zender M; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Heinlein M; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Rampal R; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Weinberg RS; New York Blood Center, New York, NY 10065, USA.
  • Hoffman R; Department of Medicine, Mount Sinai Hospital, New York, NY 10029, USA.
  • Sellers WR; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
  • Hofmann F; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Murakami M; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Baffert F; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Gaul C; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland.
  • Radimerski T; Novartis Institutes for Biomedical Research, Basel 4056, Switzerland. Electronic address: thomas.radimerski@novartis.com.
  • Levine RL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: leviner@mskcc.org.
Cancer Cell ; 28(1): 15-28, 2015 Jul 13.
Article em En | MEDLINE | ID: mdl-26175413
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Janus Quinase 2 / Transtornos Mieloproliferativos / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Janus Quinase 2 / Transtornos Mieloproliferativos / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos